title: [Optimization of the treatment of chronic obstructive pulmonary disease in men with androgen deficiency].
abstract: Chronic obstructive pulmonary disease (COPD) is a widespread condition markedly deteriorating quality of life; it is the fourth most frequent cause of death after cardiovascular diseases, diabetes mellitus and injuries. There is significant association between the severity of androgen deficiency occurrence, duration and pharmacotherapy of COPD. Androgen deficiency in men should be regarded as a new systemic pathogenetic mechanism of COPD complicating its clinical course, prognosis of the disease and concomitant pathologies. Therefore, pharmacotherapy of COPD should be prescribed taking into account the androgenic status of the patients.
authors: A L
authors: AL
authors: Vertkin
authors: A A
authors: AA
authors: Shakhmanaev
mesh_terms: D000728:Androgens / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood; D015897:Comorbidity; D003692:Delayed-Action Preparations; D003863:Depression / Q000503:physiopathology*; D016903:Drug Monitoring; D006801:Humans; D007006:Hypogonadism / Q000097:blood / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D029424:Pulmonary Disease, Chronic Obstructive / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology / Q000523:psychology; D011788:Quality of Life; D012129:Respiratory Function Tests / Q000379:methods; D012307:Risk Factors; D012426:Russia; D013739:Testosterone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D016896:Treatment Outcome
chemical_list: D000728:Androgens; D003692:Delayed-Action Preparations; D013739:Testosterone; C010792:testosterone undecanoate